Princeton, New Jersey

Intellectual property in China 

 Particular patent, data exclusivity and trademark knowledge and strategies that are useful
for life science companies operating in China.

Useful Links


IPI Academy:  Best Practices for Doing Business with IP in China Training Course


Developments on Early Resolution Mechanism for Pharmaceutical Patent Disputes in China
Recorded On:  Apr 04, 2022:  Speakers: Gary M. Hnath (Mayer Brown LLP), Hans She (Fangda Partners), Jing Zhang (Mayer Brown LLP), Tingting Liao (Fangda Partners).  Practicing Law Institute Item #:348352

Recommended articles 

Navigating China’s new protections for life science patents.  Asia Business Law Journal, 21 May 2024.  Navigating China’s new protections for life science patents


The commercialization of pharmaceutical patents in China

James Hou (Author)
"Presenting detailed analysis of the industrialization of pharmaceutical patents in China, this timely book explores a range of related topics including a comparison of the ideal and existing state of the pharmaceutical market and patent industrialization. It argues that the core purpose of the industrialization of pharmaceutical patents is to promote the development of the local pharmaceutical industry whilst also protecting society's right to safe and effective medication."
eBook, English, 2021

China has made significant strides in enhancing patent protection for life sciences. 

Introduced in 2021, this e Patent Linkage System allows for patent disputes to be resolved before the China National Intellectual Property Administration (CNIPA) or the Beijing Intellectual Property Court. This system is similar to the US Hatch-Waxman Act but has some differences, such as shorter regulatory stays and dual forums for dispute resolutions.

Patent Term Extension (PTE) and Patent Term Adjustment (PTA) provisions allow for extensions to the patent term to compensate for delays in regulatory approval processes.

The revised patent law has increased statutory damages and introduced punitive damages, making it more financially viable for patentees to pursue infringement cases.

These changes are intended to strengthen patent protection and align with China's focus on drug innovation.

Free course on essentials of life science IP in China

Write your awesome label here.

POA Participating IP Firms in China- 2025

None to date.   
Created with